Chemed Research and Development Expenses 2010-2024 | CHE

Chemed annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Chemed research and development expenses for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Chemed research and development expenses for the twelve months ending September 30, 2024 were $0M, a NAN% increase year-over-year.
  • Chemed annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • Chemed annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
  • Chemed annual research and development expenses for 2021 were $0B, a NAN% decline from 2020.
Chemed Annual Research and Development Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Chemed Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $8.459B $2.264B
Chemed Corporation purchases, operates and divests subsidiaries engaged in diverse business activities. The company's operating businesses are managed on a decentralized basis. Chemed currently operates as two wholly-owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS Healthcare segment provides hospice and palliative care services for patients with terminal illnesses. VITAS offer all levels of hospice care in a given market, including routine home care, inpatient care and continuous care. Roto-Rooter segment provides plumbing and drain-cleaning services to both residential and commercial customers. It provides repair and maintenance services to residential and commercial accounts using the Roto-Rooter registered service marks. Such services include plumbing and sewer, drain and pipe cleaning. They are delivered through company-owned and operated territories, independent contractor-operated territories and franchised locations.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $20.039B 12.12
Quest Diagnostics (DGX) United States $17.877B 18.12
DaVita (DVA) United States $12.667B 16.38
Encompass Health (EHC) United States $10.405B 24.53
Elanco Animal Health (ELAN) United States $7.054B 16.79
RadNet (RDNT) United States $6.388B 141.61
Option Care Health (OPCH) United States $3.890B 18.43
Amedisys (AMED) United States $3.035B 21.60
LifeStance Health (LFST) United States $2.828B 0.00
Addus HomeCare (ADUS) United States $2.320B 27.22
Astrana Health (ASTH) United States $2.297B 36.01
U.S Physical Therapy (USPH) United States $1.428B 37.54
Pennant (PNTG) United States $1.162B 46.99
Aveanna Healthcare Holdings (AVAH) United States $1.149B 0.00
Atai Life Sciences (ATAI) Germany $0.265B 0.00
Daxor (DXR) United States $0.042B 0.00
Psychemedics (PMD) United States $0.014B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.014B 0.00
ATI Physical Therapy (ATIP) United States $0.011B 0.00
Ontrak (OTRK) United States $0.008B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00